We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

20 Years ProBioGen

20 Years ProBioGen

20 Years ProBioGen

20 Years ProBioGen

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "20 Years ProBioGen"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

On the occasion of its 20th anniversary, ProBioGen AG has announced to invest 20€ million and to double its workforce. CEO Dr. Wieland Wolf welcomed scientific, business and political guests in a ceremony in Berlin on September 4, 2014.

On behalf of pharmaceutical and biotech companies ProBioGen is developing novel biotechnological processes for the production of biopharmaceutical drug substances to treat serious diseases. The service spectrum ranges from cell line and process development up to GMP contract manufacturing.

In addition, the Berlin scientists develop innovative technologies to improve biotechnologically active substances and by virtue of their recognized scientific excellence created an extensive portfolio of proprietary rights for optimized biopharmaceutical manufacturing.

In recent times, licenses were granted to several global pharmaceutical companies, including Boehringer Ingelheim and Novartis. Beyond that, ProBioGen will further exploit its internal potential for the development of production cell lines, process engineering and GMP manufacturing of biopharmaceuticals.

"Together with our parent company, we will continue to expand and invest in Berlin," comments Dr. Wieland Wolf. "With an investment of around 20 million euros, we will strengthen our market position, add two additional disposable 1000L bioreactors and, within the next two years, will double our staff from currently 75 highly skilled and dedicated employees" says the CEO about ProBioGen's further growth.

Dr. Wafik Bardissi, chairman of the board, announced on behalf of Minapharm Pharmaceuticals to continually invest in its two biotech sites, Berlin and Cairo, and in the development of new drugs, using synergies from both sites. The primary objective is to deliver innovative and affordable medications for patients in Egypt and other low-income countries.

As part of the ceremony the ProBioGen Innovation Prize was granted by CSO Dr. Volker Sandig to molecular biologist Thomas Rose. Through his scientific research to increase cellular productivity ProBioGen now has available "super producers by stimulating the cellular secretion apparatus".

Through a unique molecular biological intervention with the cell metabolism he was able to tremendously increase the cellular production capacity and thus achieve a competitive advantage for ProBioGen.